ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response.

RPEP-065112022Sousa, Luana Guimaraes de; Rajapakshe, Kimal; Rodriguez Canales, Jaime; Chin, Renee L; Feng, Lei; Wang, Qi; Barrese, Tomas Z; Massarelli, Erminia; William, William; Johnson, Faye M; Ferrarotto, Renata; Wistuba, Ignacio; Coarfa, Cristian; Lee, Jack; Wang, Jing; Melief, Cornelis J M; Curran, Michael A; Glisson, Bonnie S

evidence

This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.

Read the original research

ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response.

Journal for immunotherapy of cancer, 10(2)

View on PubMed ↗Publisher’s paper ↗

Citation

Sousa, Luana Guimaraes de; Rajapakshe, Kimal; Rodriguez Canales, Jaime; Chin, Renee L; Feng, Lei; Wang, Qi; Barrese, Tomas Z; Massarelli, Erminia; William, William; Johnson, Faye M; Ferrarotto, Renata; Wistuba, Ignacio; Coarfa, Cristian; Lee, Jack; Wang, Jing; Melief, Cornelis J M; Curran, Michael A; Glisson, Bonnie S. (2022). ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response.. Journal for immunotherapy of cancer, 10(2). https://doi.org/10.1136/jitc-2021-004232